May 7 |
AstraZeneca concludes equity investment in Cellectis
|
May 2 |
Cellectis announces CFO departure
|
May 2 |
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
|
Apr 29 |
Cellectis GAAP EPS of -$0.64 misses by $0.43, revenue of $1.99M misses by $14.13M
|
Apr 29 |
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
|
Apr 22 |
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
|
Apr 10 |
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
|
Apr 8 |
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
|
Jan 22 |
Cellectis: Pushing A Different Kind Of CAR-T Up The Hill
|
Dec 22 |
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
|